Dont Get Blindsided: The Critical Drug Patent Mistakes to Avoid in MA Due Diligence
In Massachusetts, a single overlooked patent detail can turn a routine diligence sprint into a costly timelineand a valuation problem you cant easily explain to investo…

Post-Approval Patents: The Hidden LOE Risk Map Pharma Teams Miss
In the race from FDA approval to durable revenue, most teams obsess over the obvious: Orange Book listings, primary patents, and the litigation calendar. But the real threat to launch tim…

Post-Approval Patents: The Hidden Loe Risk Map Pharma Cant Afford to Ignore
Most teams think the patent story ends at approval.
They shouldnt.
In the post-approval world, the real risk often hides in plain sight: patents that are filed, asserted, or st…

Beyond 20 Years: What Actually Determines a Drugs Market Exclusivity
Most people think drug exclusivity is a simple countdown: You get 20 years, then generics arrive. In reality, the clock is messierand the outcome is often decided by a handful of lega…

Pharma mega-deals dont happen because of synergy alone. They happen because of exclusivitythe legal moat that turns a promising molecule into a multi-year revenue engine.
In the background of nearly every headline acquisition, partnership, or licensing…

Patent cliffs arent just a legal eventtheyre a pricing event.
When a blockbusters exclusivity window ends, the market doesnt wait for your strategy deck. It reactsfast. Generic and authorized competitors arrive, payers renegotiate, formularies shift,…

Post-Approval Isnt DoneIts Where Patent Strategy Gets Real
Most pharma teams treat patent strategy like a pre-approval exercise: file early, win the big battles, and move on. But the reality is harsherand more expensive. The period after approval is wh…

Post-approval is where the real IP game starts.
Most teams obsess over getting to approval—then quietly assume the hard part is over. It isn’t. In the months and years after launch, your product becomes a target: for generic challengers, for “evergre…

Pharma companies dont lose exclusivity because they missed a deadline. They lose it because they mismanaged risk.
In generic-drug litigation, the real battleground isnt just the patentits the strategy around it. How you defend exclusivity, how you comm…

From Humira to Keytruda: The Blueprint for Surviving the Composition of Matter Cliff
The market doesnt just move on innovationit moves on patent math. And for biopharma, few moments are as unforgiving as the composition of matter cliff: when the core p…